AngioDynamics, Inc. (NASDAQ:ANGO) Receives $19.50 Consensus Target Price from Brokerages

AngioDynamics, Inc. (NASDAQ:ANGO) has earned an average rating of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $19.50.

Several research analysts have recently weighed in on the company. Canaccord Genuity Group upped their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. HC Wainwright lifted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th.

Insider Transactions at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This represents a 26.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its holdings in shares of AngioDynamics by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after buying an additional 1,076 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares in the last quarter. Deutsche Bank AG lifted its position in AngioDynamics by 5.9% during the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock valued at $457,000 after acquiring an additional 1,992 shares during the period. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics during the 4th quarter valued at about $27,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in AngioDynamics by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after acquiring an additional 2,263 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $15.69 on Friday. The firm’s 50 day moving average price is $13.16 and its two-hundred day moving average price is $11.67. AngioDynamics has a 52-week low of $8.36 and a 52-week high of $15.73. The stock has a market cap of $648.47 million, a PE ratio of -18.03 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts predict that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Investors are encouraged by Med Tech growth and reimbursement gains, which could help offset relatively flat device sales and support AngioDynamics’ longer-term outlook. Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
• Positive Sentiment: AngioDynamics’ shares have risen 33.5% over the past three months, reflecting market confidence that Med Tech momentum can improve future results. The company also recently exceeded quarterly revenue and adjusted-loss expectations, adding support to the growth narrative. ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
• Neutral Sentiment: Brokerages collectively rate ANGO “Hold,” indicating that improving growth prospects are balanced by persistent profitability and execution risks. AngioDynamics Given Consensus Recommendation of Hold by Brokerages
• Negative Sentiment: Zacks Research maintains a “Strong Sell” rating and broadly reduced its earnings forecasts. FY2027 EPS was cut to a loss of $0.24 from $0.13, while FY2028 EPS was lowered to a loss of $0.17 from $0.04. Several quarterly estimates were also reduced, signaling expectations for slower progress toward profitability.
• Negative Sentiment: Tariffs, higher operating costs, spending requirements and ongoing losses could pressure margins. Management’s FY2027 outlook depends on Med Tech growth offsetting flat device sales, making execution especially important after the recent rally. ANGO’s FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.